Shostka G D, T'iagi S, Kulikova A I, Spiridonov V N, Kostkina M I, Vitenberg A G
Urol Nefrol (Mosk). 1990 Nov-Dec(6):39-44.
Effects of acetate and bicarbonate dialysates on tolerance to dialysis have been examined in 30 patients with chronic renal failure (CRF). Symptomatic homeostatic impairment (nausea, vomiting, headache) and cardiovascular instability (tachycardia, arrhythmia, dyspnea) were less common (p less than 0.05) in bicarbonate dialysis. The cardiovascular symptoms correlated with antihypertensive effects of acetate (p = +0.48). Tolerance to ultrafiltration was better with bicarbonate dialysis. Gas chromatographic measurement of blood acetate concentrations in 7 patients on bicarbonate dialysis showed them to be 1.4 +/- 0.31 mmol/l at the beginning of dialysis treatment and 1.7 +/- 0.24 mmol/l at its end (normal, 1.7 +/- 0.14 mmol/l). Of 26 patients on acetate dialysis, 9 patients showed initial and late acetate concentrations of 1.7 +/- 0.26 and 2.5 +/- 0.23 mmol/l, respectively, while in 17 patients an initial concentration of 4.8 +/- 0.32 mmol/l rose to 9.0 +/- 1.1 mmol/l at the end of the treatment (p less than less than 0.01). Dialysis-induced complications had a higher incidence in the latter group (p less than 0.02). Acetate dialysis was poorly tolerated by 65% of the patients. The intolerance was aggravated by myocardial lesions and slow acetate turnover indicated by blood acetate concentrations above 7-8 mmol/l.
在30例慢性肾衰竭(CRF)患者中,研究了醋酸盐和碳酸氢盐透析液对透析耐受性的影响。碳酸氢盐透析时,症状性内环境紊乱(恶心、呕吐、头痛)和心血管不稳定(心动过速、心律失常、呼吸困难)较少见(p<0.05)。心血管症状与醋酸盐的降压作用相关(p = +0.48)。碳酸氢盐透析时对超滤的耐受性更好。对7例接受碳酸氢盐透析患者的血液醋酸盐浓度进行气相色谱测量,结果显示透析治疗开始时为1.4±0.31 mmol/L,结束时为1.7±0.24 mmol/L(正常范围为1.7±0.14 mmol/L)。在26例接受醋酸盐透析的患者中,9例患者的初始和后期醋酸盐浓度分别为1.7±0.26和2.5±0.23 mmol/L,而在17例患者中,初始浓度为4.8±0.32 mmol/L,治疗结束时升至9.0±1.1 mmol/L(p<<0.01)。后一组透析引起的并发症发生率更高(p<0.02)。65%的患者对醋酸盐透析耐受性差。心肌病变以及血液醋酸盐浓度高于7 - 8 mmol/L所表明的醋酸盐周转缓慢会加重不耐受情况。